Paper17516712
Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma.
Rao VP and 1 other. BioDrugs, 2007. Cited by 153 papers, by iCite.
Cite this record
ConductScience Library. Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. Papers, record 17516712. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17516712
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Enzyme Inhibitors | Major topic |
| Glaucoma | Major topic |
| Intracellular Signaling Peptides and Proteins | Major topic |
| Protein Serine-Threonine Kinases | Major topic |
| rho GTP-Binding Proteins | Major topic |
| Animals | |
| Aqueous Humor | |
| Axons | |
| Eye | |
| Ganglia | |
| Humans | |
| Muscle Contraction | |
| Muscle, Smooth | |
| Nerve Regeneration | |
| Regional Blood Flow | |
| Trabecular Meshwork | |
| rho-Associated Kinases |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| EY013573 | NEI NIH HHS | United States | R01EY013573 | PubMed and NIH | NIH RePORTER |
| EY12201 | NEI NIH HHS | United States | R01EY012201 | PubMed and NIH | NIH RePORTER |
Cited by85
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 153 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42603137 | Preparation of a new fixed-combination carteolol-netarsudil ophthalmic solution via one-pot pH-adjusting solubilization strategy for glaucoma treatment. | Drug Deliv | 2026 | https://conductscience.org/library/papers/42603137 | PubMed |
| 42317267 | Vascular regeneration and blood flow recovery in glaucoma. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42317267 | PubMed |
| 42274198 | Effects of Ripasudil on Mouse Subconjunctival Immune Cell Motility Activated by Monocyte Chemoattractant Protein-1. | Invest Ophthalmol Vis Sci | 2026 | https://conductscience.org/library/papers/42274198 | PubMed |
| 41851243 | Isobaric quantitative proteomics reveals altered extracellular matrix, cytoskeletal, and degradation pathways in glaucomatous trabecular meshwork cells. | Sci Rep | 2026 | https://conductscience.org/library/papers/41851243 | PubMed |
| 40283958 | Rho Kinase (ROCK) Inhibitors in the Treatment of Glaucoma and Glaucoma Surgery: A Systematic Review of Early to Late Phase Clinical Trials. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40283958 | PubMed |
| 39827971 | Optimized PLGA encapsulated SA-2 nanosuspension exhibits sustained intraocular pressure reduction in the mouse microbead occlusion model of ocular hypertension. | Eur J Pharm Sci | 2025 | https://conductscience.org/library/papers/39827971 | PubMed |
| 39818739 | Advancements and Prospects in Nanorobotic Applications for Ophthalmic Therapy. | ACS Biomater Sci Eng | 2025 | https://conductscience.org/library/papers/39818739 | PubMed |
| 39565302 | The Mechanisms of Neuroprotection by Topical Rho Kinase Inhibition in Experimental Mouse Glaucoma and Optic Neuropathy. | Invest Ophthalmol Vis Sci | 2024 | https://conductscience.org/library/papers/39565302 | PubMed |
| 39115865 | Activation of the ROCK/MYLK Pathway Affects Complex Molecular and Morphological Changes of the Trabecular Meshwork Associated With Ocular Hypertension. | Invest Ophthalmol Vis Sci | 2024 | https://conductscience.org/library/papers/39115865 | PubMed |
| 39080269 | CRISPR-CasRx-mediated disruption of Aqp1/Adrb2/Rock1/Rock2 genes reduces intraocular pressure and retinal ganglion cell damage in mice. | Nat Commun | 2024 | https://conductscience.org/library/papers/39080269 | PubMed |
| 38983065 | Role of integrins in the development of fibrosis in the trabecular meshwork. | Front Ophthalmol (Lausanne) | 2023 | https://conductscience.org/library/papers/38983065 | PubMed |
| 38542203 | Ripasudil as a Potential Therapeutic Agent in Treating Secondary Glaucoma in HTLV-1-Uveitis: An In Vitro Analysis. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38542203 | PubMed |
| 38416395 | Rho Kinase Inhibitors: Strategies in Glaucoma Treatment in Older Adults. | Drugs Aging | 2024 | https://conductscience.org/library/papers/38416395 | PubMed |
| 38399328 | Chemical Insights into Topical Agents in Intraocular Pressure Management: From Glaucoma Etiopathology to Therapeutic Approaches. | Pharmaceutics | 2024 | https://conductscience.org/library/papers/38399328 | PubMed |
| 38242088 | A multi-cohort genome-wide association study in African ancestry individuals reveals risk loci for primary open-angle glaucoma. | Cell | 2024 | https://conductscience.org/library/papers/38242088 | PubMed |
| 38001960 | Therapeutic Potential of Antioxidants and Hybrid TEMPOL Derivatives in Ocular Neurodegenerative Diseases: A Glimpse into the Future. | Biomedicines | 2023 | https://conductscience.org/library/papers/38001960 | PubMed |
| 37873757 | Connective tissue growth factor: Role in trabecular meshwork remodeling and intraocular pressure lowering. | Exp Biol Med (Maywood) | 2023 | https://conductscience.org/library/papers/37873757 | PubMed |
| 37332549 | Efficacy of ripasudil in reducing intraocular pressure and medication score for ocular hypertension with inflammation and corticosteroid. | Int J Ophthalmol | 2023 | https://conductscience.org/library/papers/37332549 | PubMed |
| 36936709 | Exosomal miR‑152‑5p/ARHGAP6/ROCK axis regulates apoptosis and fibrosis in cardiomyocytes. | Exp Ther Med | 2023 | https://conductscience.org/library/papers/36936709 | PubMed |
| 36230968 | The Effects of Cannabidiol on Aqueous Humor Outflow and Trabecular Meshwork Cell Signaling. | Cells | 2022 | https://conductscience.org/library/papers/36230968 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ROCK1 | 6093 | PubTator's text mining | https://conductscience.org/library/genes/6093 | NCBI Gene |
| ROCK2 | 9475 | PubTator's text mining | https://conductscience.org/library/genes/9475 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17516712
GET https://conductscience.org/api/papers/v1/17516712/cited_by?page=2